Microbiome Dynamics: Advancing Therapeutic Development in Health and Disease
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Microbiology".
Deadline for manuscript submissions: 16 February 2026 | Viewed by 68
Special Issue Editors
Interests: Microbiome therapeutics, Microbiome biomarker, 'Host-Microbiome-Pathogen' metabolic network
Interests: microbiome therapeutics; microbiome biomarker; microbiome-based cosmetics
2. Human Microbiome Medical Research Center (HM·MRC), School of Medicine, Soonchunhyang University, 22, Soonchunhyang-ro, Sinchang-myeon, Asan-si 31538, Republic of Korea
Interests: microbiome-based therapeutics; microbiome biomarkers; host-pathogen-microbiome interactions; autophagy and microbiome interplay; microbiome in personalized and predictive medicine
Special Issue Information
Dear Colleagues,
The development of microbiome-based therapeutics represents a transformative frontier in biomedical innovation. As our understanding of host–microbiome interactions deepens, microbiota-targeted interventions are increasingly being recognized as promising approaches for managing metabolic, inflammatory, and neurodegenerative diseases, as well as cancer. Moreover, their therapeutic potential is being actively explored for high-risk infectious diseases, including antibiotic-resistant superbugs and tuberculosis, where conventional strategies often fall short.
This Special Issue, entitled “Microbiome Dynamics: Advancing Therapeutic Development in Health and Disease”, encompasses the full continuum of microbiome therapeutic development—from early-stage discovery to clinical validation and real-world application. A key focus is the identification and functional analysis of previously uncharacterized microbial taxa and novel next-generation probiotics (NGPs). Disease-specific metagenomic profiling for microbial biomarker discovery, followed by validation through preclinical models—including animal studies and artificial human microbiome simulators that replicate in vivo gut environments—is highly relevant for the rational design of live biotherapeutics.
We welcome research utilizing multi-omics approaches—metagenomics, metatranscriptomics, metabolomics—to dissect host–microbiome–metabolite interactions. The quantification of bioactive compounds such as short-chain fatty acids (SCFAs), bile acids, and tryptophan metabolites offers mechanistic insights into microbiome-driven effects. Studies addressing upstream strain optimization, scalable fermentation, GMP-compliant manufacturing, and downstream clinical trial outcomes for both pharmaceutical and functional food applications are also within scope.
By bridging basic science, advanced modeling systems, and clinical translation, this Special Issue seeks to accelerate the development of precision-targeted microbiome therapeutics for both infectious and non-infectious diseases.
Dr. Hoonhee Seo
Dr. Sukyung Kim
Dr. Md Abdur Rahim
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- next-generation probiotics (NGPs)
- microbiome-based therapeutics
- metagenomics and multi-omics integration
- microbial biomarkers
- short-chain fatty acids (SCFAs)
- artificial human microbiome simulators
- GMP-scale production
- clinical translation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
